Adipositas - Ursachen, Folgeerkrankungen, Therapie 2021; 15(03): 158-159
DOI: 10.1055/s-0041-1735690
Abstracts
Wiesbaden: Adipositas-Kongress 2021

3 Efficacy and Safety of Semaglutide 2.4 mg Once-Weekly in Adults With Overweight or Obesity and Type 2 Diabetes (STEP 2)

Melanie Davies
1   Leicester General Hospital, Leicester, Vereinigtes Königreich
,
Louise Faerch
2   Novo Nordisk, Soborg, Dänemark
,
Ole Jeppesen
2   Novo Nordisk, Soborg, Dänemark
,
Arash Pakseresht
2   Novo Nordisk, Soborg, Dänemark
,
Sue Pedersen
3   ENDO Diabetes & Endocrinology Clinic Calgary, Calgary, Kanada
,
Leigh Perreault
4   University of Colorado Hospital, Denver, USA
,
Julio Rosenstock
5   Dallas Diabetes Research Center at Medical City, Dallas, USA
,
René Gollan
6   Novo Nordisk, Mainz, Deutschland
,
Iichiro Shimomura
7   Osaka University, Osaka, Japan
,
Adie Viljoen
8   Borthwick Diabetes Research Centre, Lister Hospital, Stevenage, Vereinigtes Königreich
,
Thomas Wadden
9   University of Pennsylvania, Philadelphia, USA
,
Ildiko Lingvay
10   Southwestern Medical Center, Dallas, USA
› Author Affiliations
› Further Information
Also available at
 

Zusammenfassung

Semaglutide 2.4 mg, as adjunct to lifestyle intervention, was efficacious for weight management in adults with overweight or obesity and T2D, providing significantly greater weight loss vs. placebo and semaglutide 1.0 mg at week 68.



Publication History

Article published online:
24 September 2021

© 2021. Thieme. All rights reserved.

Georg Thieme Verlag KG
Rüdigerstraße 14, 70469 Stuttgart, Germany